Several companies within our portfolio raised significant capital or were awarded prestigious grants.
Congenica completed a £39 million Series C round, Gyroscope Therapeutics completed a £50 million Series B financing and Bicycle Therapeutics added more than $60 million to its cash resources during Q3 2020 from ATM offerings and debt financing.
A consortium led by Riverlane was awarded a £7.6 million grant from the government's Industrial Challenge Strategy Fund to deploy a highly innovative quantum operating system. Exvastat won two European grants one of which was part of a consortium awarded a €3.6 million Innovative Medicines Initiative grant to fund clinical study of imatinib in the treatment of COVID-19-associated ARDS with its collaborators at Vrije Universiteit medical centre (VUmc) in Amsterdam.
Riverlane marked a ‘hello world’ moment in September, with the successful trial of its quantum operating system Deltaflow.OS®, using quantum hardware belonging to leading trapped-ion company, Oxford Ionics.
Audio Analytic announced that 2021 will be the year smartphones understand the acoustic world around us when its ai3-nano™ compact sound recognition technology was pre-certified and optimised to run on the new Snapdragon 888 5G Mobile Platform. The Snapdragon 888 will be used as the basis for Android smartphones arriving in 2021 and Audio Analytic’s AI technology opens up a range of exciting and innovative capabilities for OEMs. You can read more in our blog here.
Congenica launched Congenica Express, an update to its clinical decision support platform that will provide automated classification, evidence and reporting of recurrent ‘known’ variants that customers observe in their rare disease cases, significantly saving time while maximizing diagnostic yield and laboratory throughput and enabling complex genomic data interpretation and reporting in as little as 5 minutes.
Finally, Origami Energy announced that its technology platform will play a key role in the UK's largest vehicle-to-grid site, the Bus2Grid Innovation project.
Bicycle Therapeutics expanded its clinical pipeline with two new programmes having entered the clinic in 2020. And the first patient was dosed in the phase IIa trial of Bicycle® Toxin Conjugate BT1718.
Gyroscope Therapeutics received FDA clearance for orbit subretinal delivery system, FDA Fast Track Designation was granted for GT005, the first patient received investigational gene therapy and the first patient was dosed in the Phase II HORIZON Trial.
Exvastat started a Phase II trial of oral imatinib in hospitalised patients with respiratory symptoms associated with COVID-19 infection.
One of our favourite highlights is seeing the technological advances and hard work of our founders and companies recognised in awards. Below is a small selection from 2020.